Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Profiling Protein Aggregate Size Using Single-Molecule Array Technology.

Analytical chemistry·2026
Same author

Lifestyle interventions for dementia prevention in low- and middle-income countries: a systematic review.

BMJ global health·2026
Same author

Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

The contribution of apolipoprotein E genetic variation to dementia risk in British South Asians.

Brain communications·2026
Same author

Non-verbal dichotic listening: A new cognitive hearing test for dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

The Global Parkinson's Genetics Program (GP2): Advancing genetic discovery and capacity building worldwide.

Journal of Parkinson's disease·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Faiza G Durrani1, Charles R Marshall2, Sheena Waters2

  • 1Queen Mary University of London, London, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

听觉认知测试显示,早期发现阿尔茨海默病 (AD) 是有前途的,有助于痴呆风险分层. 这项研究评估了数字听觉评估与生物标志物相结合,以获得准确和可访问的大脑健康评估.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 老年学是一门学科.
  • 生物标志物 生物标志物

背景情况:

  • 阿尔茨海默氏病 (AD) 与听觉功能障碍有关,特别是语音噪音感知障碍.
  • 较差的听觉功能与认知能力下降和AD易受伤害的大脑区域灰质减少有关.
  • 听觉认知可以作为早期大脑健康评估和痴呆风险分层的成本效益高的工具.

研究的目的:

  • 评估听觉感知功能评估与血液生物标志物一起用于早期痴呆症诊断的实用性.
  • 开发一种可扩展的数字测试,用于中央听觉处理,作为早期痴呆症诊断工具 (DIADEM研究).
  • 评估听觉认知对临床诊断,认知衰退和认知症状患者痴呆症进展的预测价值.

主要方法:

  • 从17个NHS记忆诊所招募了600名参与者,其中包括100名健康对照.
  • 使用语音噪音,语音退化和言语声测试,纯音声测量,认知评估 (CDR,RUDAS/MMSE),血液生物标志物 (pTau-217,NfL) 和MRI.
  • 随访两年,定期评估认知和听觉功能.

主要成果:

  • 概念验证在区分AD患者与健康对照者和跟踪疾病进展方面表现出高准确性 (AUC0.91).
  • 评估单独和生物标志物 (pTau217,NfL) 的听觉感知测试,用于诊断和预后的认知症状的个体.
  • 审查数字审计评估方法的文化公平性和成本效益.

结论:

  • 开发基于听觉认知测量的可扩展,文化公平和精确的数字工具可以彻底改变早期痴呆症诊断.
  • 改善获得及时和公平的痴呆症诊断的机会.
  • 支持认知症状和潜在痴呆症患者的早期治疗和护理干预措施.